Research Article

Estimating the Proportion of Asymptomatic COVID-19 Cases in an Italian Region with Intermediate Incidence during the First Pandemic Wave: An Observational Retrospective Study

Domenico Martinelli,1 Francesca Fortunato,1 Sara Mazzilli,2,3 Lucia Bisceglia,4 Pier Luigi Lopalco,5 and Rosa Prato1

1Polyclinico Riuniti Foggia Hospital, Hygiene Unit, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy
2Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy
3Scuola Normale Superiore, Pisa, Italy
4Strategic Regional Health and Social Agency of Puglia (AReSS Puglia), Bari, Italy
5Department of Biological and Environmental Sciences and Technology, University of Salento, Lecce, Italy

Correspondence should be addressed to Rosa Prato; rosa.prato@unifg.it

Received 31 July 2021; Revised 1 December 2021; Accepted 15 December 2021; Published 5 January 2022

Academic Editor: Marcello Maida

Copyright © 2022 Domenico Martinelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Early in the COVID-19 pandemic, asymptomatic transmission represented an important challenge for controlling the spread of SARS-CoV-2 through the traditional public health strategies. Further understanding of the contribution of asymptomatic infections to SARS-CoV-2 transmission has been of crucial importance for pandemic control. We conducted a retrospective epidemiological study to characterize asymptomatic COVID-19 cases occurred in the Apulia region, Italy, during the first epidemic wave of COVID-19 outbreak (February 29-July 7, 2020). We analyzed data collected in a regional platform developed to manage surveillance activities, namely, investigation and follow-up of cases and contacts, contact tracing, and laboratory and clinical data collection. We included all asymptomatic cases that were laboratory-confirmed during the appropriate follow-up, defined as persons infected with SARS-CoV-2 who did not develop symptoms/clinical signs of the disease. Between February 29 and July 7, 2020, a total of 4,536 cases were diagnosed with COVID-19 among 193,757 tests performed. The group of persons with asymptomatic SARS-CoV-2 infection consisted of 903 cases; the asymptomatic proportion was 19.9% (95% CI: 18.8-21.1%); this decreased with increasing age (OR: 0.89, 95% CI: 0.83-0.96; \( p = 0.001 \)), in individuals with underlying comorbidities (OR: 0.55, 95% CI: 0.41-0.73; \( p < 0.001 \)), and in males (OR: 0.69, 95% CI: 0.54-0.87; \( p = 0.002 \)). The median asymptomatic SARS-CoV-2 RNA positive period was 19 days (IQR: 14-31) and the cumulative proportion of persons with resolution of infection 14 days after the first positive PCR test was 74%. As the public health community is debating the question of whether asymptomatic and late spreaders could sustain virus transmission in the communities, such cases present unique opportunities to gain insight into SARS-CoV-2 adaptation to human host. This has important implications for future COVID-19 surveillance and prevention.

1. Introduction

SARS-CoV-2 is a novel coronavirus causing the current pandemic [1], which has resulted in millions of infections and hundreds of thousands of deaths worldwide. A total of 11,500,302 coronavirus disease 2019 (COVID-19) cases were diagnosed in the world during the initial wave of the epidemic (as of July 7, 2020). Exactly 137 days since the first confirmed COVID-19 case was announced, Italy was the eleventh most affected country, with 241,819 total cases and 34,869 deaths [2], mainly concentrated in the Northern area of the country, particularly in Lombardy, Piedmont, ...
Emilia-Romagna, Veneto, and Liguria (80% of cases diagnosed at national level). By contrast, the COVID-19 cumulative incidence remained substantially lower in the central and southern regions [3, 4].

The clinical outcomes of SARS-CoV-2 vary from asymptomatic infection to a mild-to-severe or critical disease [5, 6]. Since COVID-19 bursts onto the global scene, asymptomatic transmission of SARS-CoV-2 has appeared as the “Achilles’ heel” of COVID-19 pandemic control through the traditional public health interventions [7]. Worldwide, the proportion of asymptomatic infection could be estimated to be 10.1-23.0% of all confirmed cases before May 2020 [8]. It was reported that asymptomatic infections were more common in middle-aged individuals in Shenzhen (median age: 49 years; 30.9% between 30 and 49 years) and a few younger people in Nanjing (median age: 32.5 years) [9].

Further understanding of the transmission potential of asymptomatic individuals has been crucial to improve surveillance and containment measures and estimate the likely burden of severe disease and mortality when the virus spreads in the communities [10]. However, information on the natural history of infection with SARS-CoV-2 has yet to be fully described for quantifying the contribution of persons with asymptomatic COVID-19 infection to COVID-19 transmission [11].

Here, we conducted a retrospective epidemiological study to quantify and characterize asymptomatic COVID-19 cases occurred in the Apulia region of the southern part of Italy from February 29 to July 7, 2020.

2. Materials and Methods

We analyzed data collected in a regional surveillance platform (GIAVA-COVID®) developed on the basis of the Go. Data outbreak investigation tool (WHO) [12] to manage the emergency. GIAVA-COVID® included functionalities for investigation and follow-up of cases (until having two consecutive negative RT-PCR test results at least 24 hours apart) and contacts (during the 14-day isolation period), contact tracing, demographics, and laboratory and clinical data collection. The collected information included age, sex, residence location, date of disease onset, date of diagnosis, date of hospital admission, date of COVID-19, test results (positive or negative), date of death, presence of underlying diseases, case outcomes (hospitalisation, virus clearance, and death), and disease severity (mild, moderate, severe, or critical) [6]. The disease classification was duly updated according to clinical evolution of each case. This study included all asymptomatic cases, laboratory-confirmed by RT-PCR on nasopharyngeal swabs [13] that were sampled and tested according to the Italian Ministry of Health testing policies applied during the first months of the pandemic [14]. Those included close household and nonhousehold contacts of symptomatic index cases under surveillance, healthcare professionals, and soliciting testing in case of risk exposure. An asymptomatic case was defined as a person infected with SARS-CoV-2 who did not develop clinical symptoms and chest imaging findings of the disease (never symptomatic individual) [9]. The asymptomatic proportion was defined as the proportion of infected individuals who were never symptomatic for COVID-19 among the total number of infected individuals [15]. The asymptomatic SARS-CoV-2 RNA positive period was defined as the number of days between the first positive PCR test and the first of the two serial negative PCR tests.

Categorical variables were summarized as the counts and percentages in each category. Continuous variables were expressed as the medians and interquartile ranges (IQR). Kruskal-Wallis test was applied to continuous variables. Binary and multivariate logistic regression analyses were performed to evaluate whether cases’ demographics and clinical characteristics were independently associated with having asymptomatic infection. Analysis was conducted with STATA/SE 15.0.

As this study constituted public health surveillance, ethical approval from institutional review board was not required. All data were provided and analyzed anonymously.

3. Results

Between February 29 and July 7, 2020, a total of 4,536 cases (51.1% male; median age: 56 years, IQR: 41-72; cumulative incidence: 115.5 per 100,000 inhabitants) were diagnosed with COVID-19 in the Apulia region, Italy.

The group of persons with asymptomatic SARS-CoV-2 infection consisted of 903 (53.5%) female cases among 193,757 tests performed, with median age of 50 years (IQR: 32-63). Of 335 cases for whom this information was only available, 146 (43.6%) had underlying medical conditions, the most prevalent being cardiovascular disease (24.8%), neurological diseases (6.6%), diabetes (4.2%), and chronic lung disease (3%). Comparison of demographics and clinical characteristics of asymptomatic versus symptomatic presentation following SARS-CoV-2 infection are shown in Table 1.

The asymptomatic proportion was estimated to be 19.9% (95% confidence interval (CI): 18.8-21.1%). The median asymptomatic SARS-CoV-2 RNA positive period was 19 days (IQR: 14-31), and the cumulative proportion of persons with resolution of infection 14 days after the first positive PCR test was 74% (Figure 1).

The probability of having asymptomatic infection decreased with increasing age (odds ratio for being asymptomatic with each 10-year increase in age: 0.89, 95% CI: 0.83-0.96, p = 0.001), in individuals with underlying diseases (OR: 0.55, 95% CI: 0.41-0.73, p < 0.001), and in males (OR: 0.69, 95% CI: 0.54-0.86, p = 0.002) (Table 1).

The risk of delayed resolution of infection increased with increasing age, with median asymptomatic SARS-CoV-2 RNA positive period increasing from 16.5 days (IQR: 14-26) in persons aged 0-9 years to 28 days (IQR: 18-40) in those aged 80-89 years (p < 0.001).

4. Discussion

After the end of the first epidemic wave of COVID-19 outbreak in Italy, we tried to estimate the proportion of people with SARS-CoV-2 who were asymptomatic. Findings from
Table 1: Comparison of characteristics between asymptomatic and symptomatic SARS-CoV-2 infections, Apulia region, Italy, February-July 2020.

| Characteristics                  | Asymptomatic SARS-CoV-2 infections (no. 903) | Symptomatic SARS-CoV-2 infections (no. 3,633) | Total (no. 4,536) | Logistic regression analysis |
|----------------------------------|---------------------------------------------|---------------------------------------------|-------------------|-----------------------------|
|                                  | No.  %                                      | No.  %                                      | No.  %            | Binary                      | OR  95% CI   | p    | OR  95% CI   | p    |
|                                  |                                             |                                             |                   |                             |               |      |               |      |
| Sex                              |                                             |                                             |                   |                             |               |      |               |      |
| Female                           | 483  53.49                                 | 1,734  47.73                               | 2,217  48.88      | Ref.                        |               |      | Ref.          |      |
| Male                             | 420  46.51                                 | 1,899  52.27                               | 2,319  51.12      | 0.79                        | 0.69-0.92    | 0.002 | 0.69          | 0.54-0.86 | 0.002 |
| Age group, years                 |                                             |                                             |                   |                             |               |      |               |      |
| 0-9                              | 28   3.10                                   | 47   1.29                                   | 75   1.65         | Ref.                        |               |      | Ref.          |      |
| 10-19                            | 53   5.87                                   | 80   2.20                                   | 133  2.93         | 1.11                        | 0.62-1.99    | 0.721 |               |      |
| 20-29                            | 98   10.85                                  | 284  7.82                                   | 382  8.42         | 0.58                        | 0.34-0.97    | 0.040 |               |      |
| 30-39                            | 125  13.84                                  | 370  10.18                                  | 495  10.91        | 0.56                        | 0.34-0.94    | 0.029 |               |      |
| 40-49                            | 137  15.17                                  | 499  13.74                                  | 636  14.02        | 0.46                        | 0.28-0.76    | 0.003 |               |      |
| 50-59                            | 189  20.93                                  | 696  19.16                                  | 885  19.51        | 0.45                        | 0.28-0.75    | 0.002 | 0.89          | 0.83-0.96 | 0.001 |
| 60-69                            | 100  11.07                                  | 560  15.41                                  | 660  14.55        | 0.3                         | 0.18-0.50    | <0.001 |               |      |
| 70-79                            | 63   6.98                                   | 436  12.00                                  | 499  11.00        | 0.24                        | 0.14-0.41    | <0.001 |               |      |
| 80-89                            | 77   8.53                                   | 467  12.85                                  | 544  11.99        | 0.28                        | 0.16-0.46    | <0.001 |               |      |
| ≥90                              | 33   3.65                                   | 194  5.34                                   | 227  5.00         | 0.27                        | 0.16-0.52    | <0.001 |               |      |
| Single comorbidities*            |                                             |                                             |                   |                             |               |      |               |      |
| None                             | 189  56.42                                  | 676  35.39                                  | 865  38.53        | Ref.                        |               |      | Ref.          |      |
| Cardiovascular disease           | 83   24.78                                  | 733  38.38                                  | 816  36.35        | 0.41                        | 0.37-0.54    | <0.001 |               |      |
| Diabetes                         | 14   4.18                                   | 244  12.77                                  | 258  11.49        | 0.21                        | 0.12-0.36    | <0.001 |               |      |
| Chronic pulmonary disease        | 11   3.28                                   | 232  12.15                                  | 243  10.82        | 0.17                        | 0.09-0.32    | <0.001 |               |      |
| Cancer                           | 9    2.69                                   | 141  7.38                                   | 150  6.68         | 0.23                        | 0.11-0.46    | <0.001 |               |      |
| Neurological diseases            | 22   6.57                                   | 178  9.32                                   | 200  8.91         | 0.44                        | 0.28-0.71    | 0.001 |               |      |
| Chronic kidney disease           | 3    0.90                                   | 110  5.76                                   | 113  5.03         | 0.1                         | 0.03-0.31    | <0.001 |               |      |
| Obesity                          | 5    1.49                                   | 89   4.66                                   | 94   4.19         | 0.2                         | 0.08-0.5     | 0.001 |               |      |
| Other metabolic diseases         | 10   2.99                                   | 58   3.04                                   | 68   3.03         | 0.62                        | 0.31-1.22    | 0.170 |               |      |
| Liver disease                    | 2    0.60                                   | 33   1.73                                   | 35   1.56         | 0.22                        | 0.05-0.91    | 0.037 |               |      |
| HIV                              | 2    0.60                                   | 26   1.36                                   | 28   1.25         | 0.27                        | 0.06-1.17    | 0.081 |               |      |
| At least one comorbidity         | 146  43.58                                  | 1,234 64.61                                 | 1,380 61.427      | 0.42                        | 0.33-0.53    | <0.001 | 0.55          | 0.41-0.73 | <0.001 |

Ref: reference group. *2,245 cases (335 asymptomatic and 1,910 symptomatic infections) for whom the information was available.
our study in the Apulia region showed that between 18.8% and 21.1% of people testing positive for SARS-CoV-2 during the appropriate follow-up actions were asymptomatic. These estimates were consistent with the pooled percentages of asymptomatic infections estimated in several systematic reviews and meta-analyses performed so far during the pandemic (Table 2).

However, the Lavezzo et al. prospective cohort study conducted in the Italian municipality of Vò reported much higher proportion of asymptomatic infections (42.5%) [22]. This difference could be explained by the fact that in our study, we analyzed a larger number of cases. Moreover, the retrospective nature of our study allowed us to exclude from the analysis the asymptomatic individuals who developed symptoms later during follow-up. In fact, presymptomatic patients are easily misclassified as asymptomatic if the follow-up is not long enough, and this may lead to overestimate the true burden of asymptomatic infection [8].

From the beginning of the pandemic of SARS-CoV-2, older age, prior illnesses, and male sex have emerged as risk factors [8]. Our results showed that asymptomatic infections were more common in young individuals without underlying diseases and among females. A meta-analysis for studies with younger COVID-19-positive populations (e.g., obstetric patients) found that in these younger populations, it appeared fewer people developed symptoms compared to older groups, during similar follow-up times [23]. In Italy, this could be attributed to an underestimation of younger COVID-19 cases in the early phase of the outbreak due to various detection policies that led to the restriction of testing with swab to mainly symptomatic cases. Following the period examined in this study, when the World Health Organization guidelines were relaxed and Italy entered the transition phase, the testing policy has been broadened to various screening programmes (e.g., ahead of hospital admission for other causes, diagnostic suspicion that emerge during clinical activities, and screening/tracing activities that emerge via planned tests of travellers returning to Italy from foreign countries with higher virus circulation, immigrants, and employees) [4]. As a result, between July and mid-August

### Table 2: The proportion of asymptomatic SARS-CoV-2 infections reported in different systematic reviews and meta-analyses.

| First author               | Study period                  | Total SARS-CoV-2, no. | Asymptomatic SARS-CoV-2, no. | Pooled proportions   |
|----------------------------|-------------------------------|-----------------------|-------------------------------|----------------------|
| A. Kronbichlera et al. [16]| December 1, 2019 to March 29, 2020 | NR                    | 506                           | 24.2% (SD 22.06)     |
| J. Zhu et al. [17]         | January 1 to February 28, 2020 | 3,062                 | 158                           | 11.9% (95% CI: 2.9-25.8%) |
| C. Chen et al. [18]        | January 1 to May 13, 2020     | 20,152                | NR                            | 13.34% (95% CI: 10.86–16.29%) |
| J. He et al. [8]           | Before May 20, 2020           | 50,155                | 1,430                         | 15.6% (95% CI: 10.1-23.0%) |
| D. Buitrago-Garcia et al. [19]| March 25 to June 10, 2020    | 6,616                 | 1,287                         | 20% (95% CI: 17-25%)  |
| M. Alene et al. [20]       | June 1 to December 9, 2020   | 6,071                 | 1,917                         | 25% (95% CI: 16-38%)  |
| P. Sah et al. [21]         | January 1, 2020 to April 2, 2021 | 17,272              | 7,222                         | 35.1% (95% CI: 30.7-39.9%) |

NR: not reported. SD: standard deviation.
2020, when the second wave pandemic started, it was reported that overall 76% of asymptomatic cases seen in the Apulia region were aged between 0 and 50 years (median age: 28 years). It is likely also that the difference between the medians of age of asymptomatic cases in the two consecutive periods (50 vs. 28 years) reflected the sensitivity of case finding and diagnostic protocols rather than the true disease epidemiology.

Our data showed that one in four asymptomatically infected person had a positive nucleic test result to more than four weeks after the first test (Figure 1), this may indicate that the long-term infection of SARS-CoV-2 might really do exist among asymptomatic cases. In particular, long-term carrying of the virus was more common for asymptomatic older cases than the youngest cases.

This study had two main limitations. First, in view of the reasons mentioned above, asymptomatic cases in our first outbreak cohort could have represented a peculiar, underestimated fraction of the SARS-CoV-2 asymptomatic transmission. Since the beginning of the mitigation stage in late February 2020, most Italian regions experienced a severe lack of testing material and capacity leading the Italian Ministry of Health to prioritize viral RNA testing for symptomatic people and subjects at high risk for Sars-CoV-2 infections while drastically reducing testing of the asymptomatic general population [24, 25].

Second, the peak of resolution of infection observed at 14 days (Figure 1) was an artefact of the surveillance and depended on the fact that many cases were tested at day 14 before exiting the quarantine period. Anyhow, such peak did not affect either median or Q3 value calculation that were very likely to be 19 and 31 days, respectively.

5. Conclusions

Identifying asymptomatic cases has been of crucial importance for SARS-CoV-2 in the subsequent outbreak phases. In Italy, the national weekly epidemiological bulletins reported that asymptomatic infections have represented an increasing fraction of the infected population over time (>50% [26]), also as a result of increased testing capacity for COVID-19. The presence of a large proportion of asymptomatic and late spreaders of the virus has continued to be a challenge for controlling the pandemic. Atripaldi et al. suggested that, in Italy, the rapid spread of the second outbreak since late August could have been linked to the circulation of asymptomatic individuals and to their consistent contribution to community transmission in post lockdown [27]. They might also be contributing substantially to building herd immunity in addition to the real-life effect of the ongoing mass vaccination campaign (including indirect protection). However, further research is required to learn more about on how the virus adapts to humans and its future management, including COVID-19 surveillance, strategic testing policies, and public health interventions.

Data Availability

The data that support the findings of this study are available from the Apulia Public Health Authority, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Apulia Public Health Authority.

Disclosure

An earlier version of this manuscript has been presented as a preprint in the following link: https://www.researchsquare.com/article/rs-93013/v1 [28]. Portion of this study data were presented as oral communication at the XLV Conference of the Italian Association of Epidemiology, on-line edition, held on 26–30 April 2021.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

The authors would like to thank all the patients whose data were used in this study. A special thanks to all the frontline health workers, staff at Regional Public Health Authority, staff at Local Health Units, staff at Hospitals, and staff at Laboratories across the Apulia region, for their dedication and valuable work into pandemic control.

References

[1] J. Chen, “Pathogenicity and transmissibility of 2019-nCoV—A quick overview and comparison with other emerging viruses,” Microbes and Infection, vol. 22, no. 2, pp. 69–71, 2020.

[2] World Health Organization, Coronavirus disease (COVID-19) Situation Report – 169, 2020, https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200707-covid-19-sitrep-169.pdf?sfvrsn=c6c69c88.

[3] EpiCentro-Epidemiology for Public Health and Italian National Institute of Health (Istituto Superiore di Sanità), COVID-19 integrated surveillance data in Italy, 2020, https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrata-COVID-19_30-giugno-2020.pdf.

[4] F. Riccardo, M. Ajelli, X. D. Andrianou et al., "Epidemiological characteristics of COVID-19 cases and estimates of the reproductive numbers 1 month into the epidemic, Italy, 28 January to 31 March 2020," Euro Surveillance, vol. 25, no. 49, article 2000790, 2020.

[5] National Health Commission of People’s Republic of China, Diagnostic and treatment plan of coronavirus disease 2019, 2020, http://www.nhc.gov.cn/yzwj/s7653p/202003/46c9294a7df4e4e80dc7f5912eb1989.shtml.

[6] World Health Organization, Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected, 2020, https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-ncov-infection-is-suspected.

[7] M. Gandhi, D. S. Yokoem, and D. V. Havlir, “Asymptomatic transmission, the Achilles’ heel of current strategies to control Covid-19,” New England Journal of Medicine, vol. 382, no. 22, pp. 2158–2160, 2020.
[8] J. He, Y. Guo, R. Mao, and J. Zhang, “Proportion of asymptomatic coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis,” Journal of Medical Virology, vol. 93, no. 2, pp. 820–831, 2020.
[9] Z. Gao, Y. Xu, C. Sun et al., “A systematic review of asymptomatic infections with COVID-19,” Journal Of Microbiology, Immunology And Infection, vol. 54, no. 1, pp. 12–16, 2021.
[10] S. W. Park, D. M. Cornforth, J. Dushoff, and J. S. Weitz, “The time scale of asymptomatic transmission affects estimates of epidemic potential in the COVID-19 outbreak,” Epidemics, vol. 31, 2020.
[11] A. Sakurai, T. Sasaki, S. Kato et al., “Natural history of asymptomatic SARS-CoV-2 infection,” New England Journal of Medicine, vol. 383, no. 9, pp. 885–886, 2020.
[12] World Health Organization, Go.Data: managing complex data in outbreaks, 2021, https://www.who.int/godata.
[13] P. Stefanelli, G. Faggioni, A. L. Presti et al., “Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and February 2020: additional clues on multiple introductions and further circulation in Europe,” Euro Surveillance, vol. 25, no. 13, article 2000305, 2020.
[14] G. Onder, G. Rezza, and S. Brusaferro, “Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy,” JAMA, vol. 323, no. 18, pp. 1775–1776, 2020.
[15] K. Mizumoto, K. Kagaya, A. Zarebsky, and G. Chowell, “Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020,” Euro Surveillance, vol. 25, no. 10, article 2000180, 2020.
[16] A. Kronbichler, D. Kresse, S. Yoon, K. H. Lee, M. Effenberger, and J. I. Shin, “Asymptomatic patients as a source of COVID-19 infections: a systematic review and meta-analysis,” International Journal of Infectious Diseases, vol. 98, pp. 180–186, 2020.
[17] J. Zhu, P. Ji, J. Pang et al., “Clinical characteristics of 3062 COVID-19 patients: a meta-analysis,” Journal of Medical Virology, vol. 92, no. 10, pp. 1902–1914, 2020.
[18] C. Chen, C. Zhu, D. Yan et al., “The epidemiological and radiographical characteristics of asymptomatic infections with the novel coronavirus (COVID-19): A systematic review and meta-analysis,” International Journal of Infectious Diseases, vol. 104, pp. 458–464, 2021.
[19] D. Buitrago-Garcia, D. Egli-Gany, M. J. Cournette et al., “Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis,” PLoS Medicine, vol. 17, no. 9, article e1003346, 2020.
[20] M. Alene, L. Yismaw, M. A. Assemie et al., “Magnitude of asymptomatic COVID-19 cases throughout the course of infection: a systematic review and meta-analysis,” PLoS One, vol. 16, no. 3, article e0249090, 2021.
[21] P. Sah, M. C. Fitzpatrick, C. F. Zimmer et al., “Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis,” Proceedings of the National Academy of Sciences, vol. 118, no. 34, article e2109229118, 2021.
[22] E. Lavezzo, E. Franchin, C. Ciavarella et al., “Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo,” Nature, vol. 584, no. 7821, pp. 425–429, 2020.
[23] M. Yanes-Lane, N. Winters, F. Fregonese et al., “Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: a systematic review and meta-analysis,” PLoS One, vol. 15, no. 11, article e0241536, 2020.
[24] A. De Matteis, F. B. Turkmen Ceylan, M. Adrianopoli, and S. Ertel, “The contribution of testing in the fight against COVID-19: evidence from Italy,” The European Journal of Public Health, vol. 31, no. 4, pp. 913–917, 2021.
[25] M. Di Bari, D. Balzi, G. Carreras, and G. Onder, “Extensive testing may reduce COVID-19 mortality: a lesson from northern Italy,” Frontiers in Medicine, vol. 7, p. 402, 2020.
[26] EpiCentro-Epidemiology for Public Health and Italian National Institute of Health (Istituto Superiore di Sanità), COVID-19 integrated surveillance data in Italy, 2021, https://www.epicentro.iss.it/coronavirus/bollettino/Bollettino-sorveglianza-integrita-COVID-19_30-giugno-2021.pdf.
[27] L. Atripaldi, S. Sale, M. Capone et al., “Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave,” Journal of Translational Medicine, vol. 19, no. 1, p. 93, 2021.
[28] D. Martinelli, F. Fortunato, S. Mazzilli, L. Bisceglia, P. L. Lopalco, and R. Prato, Estimating the proportion of asymptomatic COVID-19 cases during the first pandemic wave in Apulia region, Italy, 2020, https://www.researchsquare.com/article/rs-93013/v1.